Source comparison
CJC-1295 No DAC vs DAC-Modified CJC-1295 — Which Formulation Fits Your Research Model
The table below distills the functional differences between Modified GRF 1-29 (marketed as CJC-1295 no DAC) and true DAC-modified CJC-1295, focusing on dosing frequency, half-life, and practical administration considerations. Plasma Half-Life ~30 minutes 5–8 d
This comparison does not assign a generated winner or score.
- The table below distills the functional differences between Modified GRF 1-29 (marketed as CJC-1295 no DAC) and true DAC-modified CJC-1295, focusing on dosing frequency, half-life, and practical administration considerations.
- Plasma Half-Life
- ~30 minutes
- 5–8 days
- The half-life difference is the defining distinction. Non-DAC clears rapidly, DAC persists for a week
- Dosing Frequency
- 1–3 times daily
- Once or twice weekly
- Daily dosing with no-DAC mimics natural pulsatile GH; weekly dosing with DAC sustains elevation
- Typical Dose Range
- 100–200 mcg per injection
- 1–2 mg per injection
- Non-DAC uses micrograms per dose; DAC uses milligrams due to longer duration
- GH Secretion Pattern
- Pulsatile, mirrors endogenous rhythm
- Sustained elevation over days
- Pulsatile patterns prevent receptor downregulation; sustained elevation risks diminished response
- Combination Protocols
- Frequently stacked with GHRPs (Ipamorelin, GHRP-2)
- Typically used alone
- Non-DAC synergizes well with GHRPs due to complementary mechanisms; DAC's long half-life complicates stacking
- Reconstitution Stability
- Use within 28 days post-reconstitution at 2–8°C
- Both require refrigeration post-reconstitution. Temperature excursions denature peptides irreversibly